Madrigal's Rezdiffra, the first-ever MASH drug, beats sales projections for 4 quarters in a row
Since its historic FDA approval in March 2024 as the first medication for MASH, Madrigal’s Rezdiffra has handily beat Wall Street’s sales projections for the fourth straight quarter.
Since its historic FDA approval in March 2024 as the first medication for MASH, Madrigal’s Rezdiffra has handily beat Wall Street’s sales projections for the fourth straight quarter.
